Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab

• Published in: Cancer management and research Vol. 14; pp. 1641 - 1651
• Main Authors: Furubayashi, Nobuki, Minato, Akinori, Negishi, Takahito, Sakamoto, Naotaka, Song, Yoohyun, Hori, Yoshifumi, Tomoda, Toshihisa, Harada, Mirii, Tamura, Shingo, Miura, Akihiro, Komori, Hiroki, Kuroiwa, Kentaro, Seki, Narihito, Fujimoto, Naohiro, Nakamura, Motonobu
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 2022; Dove; Dove Medical Press
• Subjects: Analysis; Cancer; Carcinoma; Care and treatment; Chemotherapy; Development and progression; immune-related adverse events; Medical research; Medicine, Experimental; Original Research; pembrolizumab; relative eosinophil count; urothelial carcinoma; Japan; pembrolizumab; relative eosinophil count; urothelial carcinoma; immune-related adverse events

To evaluate the association between immune-related adverse events (irAEs) and the clinical outcomes and also between irAEs and the post-treatment changes in the relative eosinophil count (REC) in advanced urothelial carcinoma (UC) patients treated with pembrolizumab. This retrospective study analyze...